Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in January

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 5,640,000 shares, a growth of 14.9% from the December 31st total of 4,910,000 shares. Based on an average trading volume of 976,100 shares, the days-to-cover ratio is presently 5.8 days.

Analyst Upgrades and Downgrades

IMUX has been the topic of several recent research reports. D. Boral Capital restated a "buy" rating and issued a $17.00 price target on shares of Immunic in a research report on Tuesday, January 7th. HC Wainwright started coverage on shares of Immunic in a report on Monday, November 25th. They set a "buy" rating and a $10.00 target price for the company. Finally, StockNews.com raised Immunic from a "sell" rating to a "hold" rating in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $12.67.

Immunic Trading Up 3.6 %

NASDAQ IMUX traded up $0.03 on Wednesday, hitting $0.98. 552,549 shares of the company's stock were exchanged, compared to its average volume of 1,063,129. The stock has a 50-day moving average of $1.08 and a 200-day moving average of $1.29. The stock has a market cap of $88.64 million, a price-to-earnings ratio of -0.80 and a beta of 1.87. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.02). During the same period in the previous year, the company earned ($0.51) EPS. As a group, analysts predict that Immunic will post -0.94 earnings per share for the current year.

Insider Transactions at Immunic

In other Immunic news, Director Richard Alan Rudick bought 87,300 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now owns 87,300 shares in the company, valued at approximately $100,395. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immunic

Hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its position in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after purchasing an additional 11,642 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after buying an additional 42,383 shares during the period. HB Wealth Management LLC bought a new stake in Immunic during the fourth quarter valued at $81,000. Jane Street Group LLC grew its holdings in Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after acquiring an additional 38,553 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Immunic in the 3rd quarter valued at about $50,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.